Roche reported a planned interim success in a Phase III adjuvant trial of its oral selective estrogen receptor degrader, giredestrant, showing the agent reduced early recurrence when given after surgery compared with standard‑of‑care. An earlier Roche statement noted the oral SERD met its pre‑specified goal at interim analysis, positioning the drug for an adjuvant approval pathway. Company disclosures described clinically meaningful reductions in recurrence risk; details on hazard ratios, safety and the statistical boundary will be important for regulators and clinicians. Roche framed the win as establishing giredestrant for an adjuvant niche where oral ER degraders can replace or complement injectable endocrine therapies. The readout further intensifies competition in endocrine therapy for breast cancer and may prompt accelerated regulatory interactions; manufacturers and oncologists will watch long‑term overall survival and tolerability data as the program advances.